Scholarlink

Background <p>Zhejiang Province, China, has implemented a free influenza vaccination program for the elderly population for five consecutive years. However, data on real-world vaccine effectiveness against influenza among the local elderly population during the 2024–2025 influenza season are still lacking.</p> Methods <p>A multicenter, retrospective test-negative design (TND) was adopted in this study. Sentinel surveillance networks were established across designated sentinel hospitals in six cities of Zhejiang Province, covering the period from October 2024 to July 2025. On a weekly basis, all or a systematic sample of patients aged ≥ 60 years presenting with influenza-like illness (ILI) were enrolled in the study. Epidemiological data were collected, respiratory specimens were obtained, and laboratory assays were conducted to detect influenza virus types and subtypes.</p> Results <p>Of the 4694 enrolled elderly patients with ILI, 1587 (33.81%) were influenza-positive, with A(H1N1)pdm09 being the dominant subtype (93.3%). Vaccination coverage was 32.72% (1536/4694). After adjusting for age, sex, chronic comorbidities, calendar week, and city, the overall VE was 53.3% (95% CI: 45.4–60.2). VE estimates by age group were 56.9% (95% CI: 45.8–65.8) for individuals aged 60–69 years, 51.2% (95% CI: 36.2–62.8) for 70–79 years, and 57.7% (95% CI: 37.2–71.8) for those aged ≥ 80 years. When compared with non-consecutive vaccination in the current season, VE for two, three, and four consecutive seasons was 44.6% (95% CI: 31.1–55.5), 35.5% (95% CI: 17.5–49.7), and 38.6% (95% CI: 18.8–53.6), respectively. Protection waned from 58.0% (95% CI: 37.6–71.7) within 59 days post-vaccination to 42.8% (95% CI: 33.4–50.9) between 60 and 180 days. Furthermore, vaccination provided effective protection against moderate-to-severe influenza (68.8%, 95% CI: 50.0-80.6) and influenza-associated hospitalization (53.9%, 95% CI: 37.3–66.0).</p> Conclusions <p>In the 2024–2025 season in Zhejiang, influenza vaccination offered moderate protection against laboratory-confirmed influenza among adults aged ≥ 60 years. While VE waned over time, consecutive vaccination maintained moderate effectiveness. The vaccine also provided substantial protection against moderate-to-severe influenza and hospitalization.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness of seasonal influenza vaccine against dominant A(H1N1)pdm09 in adults ≥ 60 years: a multicenter test-negative design in Zhejiang, China, 2024–2025

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月25日

查看全文
  • Xinyu Liu,
  • Jialie Jin,
  • Zenghao Xu,
  • Liangliang Huo,
  • Fenghua Zhang,
  • Xiaofei Fu,
  • Yang Liu,
  • Tianfeng He,
  • Xiaowei Li,
  • Lili Wang,
  • Liyan Qian,
  • Guangming Zhang,
  • Shuangqing Wang,
  • Hui Yang,
  • Yanli Cao,
  • Lanxin Ma,
  • Ruijing Bao,
  • Jinren Pan,
  • Zhao Yu,
  • Shelan Liu,
  • Xiaoxiao Wang,
  • Jimin Sun,
  • Hangjie Zhang

摘要

Background

Zhejiang Province, China, has implemented a free influenza vaccination program for the elderly population for five consecutive years. However, data on real-world vaccine effectiveness against influenza among the local elderly population during the 2024–2025 influenza season are still lacking.

Methods

A multicenter, retrospective test-negative design (TND) was adopted in this study. Sentinel surveillance networks were established across designated sentinel hospitals in six cities of Zhejiang Province, covering the period from October 2024 to July 2025. On a weekly basis, all or a systematic sample of patients aged ≥ 60 years presenting with influenza-like illness (ILI) were enrolled in the study. Epidemiological data were collected, respiratory specimens were obtained, and laboratory assays were conducted to detect influenza virus types and subtypes.

Results

Of the 4694 enrolled elderly patients with ILI, 1587 (33.81%) were influenza-positive, with A(H1N1)pdm09 being the dominant subtype (93.3%). Vaccination coverage was 32.72% (1536/4694). After adjusting for age, sex, chronic comorbidities, calendar week, and city, the overall VE was 53.3% (95% CI: 45.4–60.2). VE estimates by age group were 56.9% (95% CI: 45.8–65.8) for individuals aged 60–69 years, 51.2% (95% CI: 36.2–62.8) for 70–79 years, and 57.7% (95% CI: 37.2–71.8) for those aged ≥ 80 years. When compared with non-consecutive vaccination in the current season, VE for two, three, and four consecutive seasons was 44.6% (95% CI: 31.1–55.5), 35.5% (95% CI: 17.5–49.7), and 38.6% (95% CI: 18.8–53.6), respectively. Protection waned from 58.0% (95% CI: 37.6–71.7) within 59 days post-vaccination to 42.8% (95% CI: 33.4–50.9) between 60 and 180 days. Furthermore, vaccination provided effective protection against moderate-to-severe influenza (68.8%, 95% CI: 50.0-80.6) and influenza-associated hospitalization (53.9%, 95% CI: 37.3–66.0).

Conclusions

In the 2024–2025 season in Zhejiang, influenza vaccination offered moderate protection against laboratory-confirmed influenza among adults aged ≥ 60 years. While VE waned over time, consecutive vaccination maintained moderate effectiveness. The vaccine also provided substantial protection against moderate-to-severe influenza and hospitalization.